USD
$0.00
(0.00%
)At Close (As of Oct 22, 2025)
$267.18M
Market Cap
-
P/E Ratio
-1.81
EPS
$15.67
52 Week High
$4.05
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $81M |
| Total Revenue | $137M |
| Cost Of Revenue | $54M |
| Costof Goods And Services Sold | $54M |
| Operating Income | -$53M |
| Selling General And Administrative | $105M |
| Research And Development | $31M |
| Operating Expenses | $136M |
| Investment Income Net | - |
| Net Interest Income | $15M |
| Interest Income | $15M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $8.4M |
| Income Before Tax | -$38M |
| Income Tax Expense | $434K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$39M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$53M |
| Ebitda | -$44M |
| Net Income | -$39M |
| Field | Value (USD) |
|---|---|
| Total Assets | $407M |
| Total Current Assets | $364M |
| Cash And Cash Equivalents At Carrying Value | $57M |
| Cash And Short Term Investments | $57M |
| Inventory | $33M |
| Current Net Receivables | $32M |
| Total Non Current Assets | $43M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $4M |
| Intangible Assets Excluding Goodwill | $4M |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $232M |
| Other Current Assets | $9.6M |
| Other Non Current Assets | - |
| Total Liabilities | $76M |
| Total Current Liabilities | $42M |
| Current Accounts Payable | $7M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $9.5M |
| Total Non Current Liabilities | $34M |
| Capital Lease Obligations | $37M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $37M |
| Other Current Liabilities | $16M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $330M |
| Treasury Stock | - |
| Retained Earnings | -$470M |
| Common Stock | $39K |
| Common Stock Shares Outstanding | $38M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$35M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $8.4M |
| Capital Expenditures | $3.4M |
| Change In Receivables | - |
| Change In Inventory | -$6.7M |
| Profit Loss | - |
| Cashflow From Investment | -$82M |
| Cashflow From Financing | $456K |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$39M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $81M |
| Total Revenue | $137M |
| Cost Of Revenue | $54M |
| Costof Goods And Services Sold | $54M |
| Operating Income | -$53M |
| Selling General And Administrative | $105M |
| Research And Development | $31M |
| Operating Expenses | $136M |
| Investment Income Net | - |
| Net Interest Income | $15M |
| Interest Income | $15M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $8.4M |
| Income Before Tax | -$38M |
| Income Tax Expense | $434K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$39M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$53M |
| Ebitda | -$44M |
| Net Income | -$39M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Quanterix Corporation is a leading life sciences innovator based in Billerica, Massachusetts, focused on revolutionizing precision health through its advanced digital immunoassay platforms. The company's proprietary technology allows for ultra-sensitive biomarker detection, empowering research and diagnostics in a variety of therapeutic areas and driving advancements in disease understanding and personalized patient care. With a strong global presence across North America, Europe, the Middle East, Africa, and Asia Pacific, Quanterix is positioned as a key player in the healthcare and diagnostics sector, committed to transforming patient outcomes and driving innovation in life sciences.